In this article:

BTIG Thinks OncoCyte’s Stock is Going to Recover

In this article:
In this article:

BTIG analyst Mark Massaro reiterated a Buy rating on OncoCyte (OCXResearch Report) yesterday and set a price target of $5.00. The company’s shares closed last Wednesday at $1.66, close to its 52-week low of $1.65.

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 11.2% and a 51.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Ginkgo Bioworks Holdings, and Lucid Diagnostics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for OncoCyte with a $4.05 average price target, which is a 90.1% upside from current levels. In a report issued on January 5, Piper Sandler also initiated coverage with a Buy rating on the stock with a $3.10 price target.

See today’s best-performing stocks on TipRanks >>

OncoCyte’s market cap is currently $153.1M and has a P/E ratio of -4.06.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.

Read More on OCX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed